Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C – GlobeNewswire
Business News
- Orphazyme provides regulatory update from FDA on arimoclomol for Niemann-Pick disease type C GlobeNewswire
- Danish ‘meme stock’ Orphazyme plunges after drug setback Reuters
- Orphazyme stock slumps 52% on FDA thumbs down for arimoclomol; cuts FY21 outlook (updated) Seeking Alpha
- Danish Meme Stock Orphazyme Cuts Outlook After Failing FDA Test BNN
- View Full Coverage on Google News
Source: Business News